Immunome (NASDAQ:IMNM) Upgraded by Barclays to Strong-Buy Rating

Posted by Francis Steltz on May 29th, 2026

Immunome (NASDAQ:IMNM – Get Free Report) was upgraded by research analysts at Barclays to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Stephens reduced their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Immunome in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Leerink Partners reduced their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $33.17.

Get Our Latest Stock Report on IMNM

Immunome Stock Performance

NASDAQ:IMNM opened at $22.54 on Thursday. The firm’s fifty day moving average is $22.06 and its 200-day moving average is $21.58. Immunome has a 52 week low of $7.96 and a 52 week high of $27.65. The firm has a market cap of $2.55 billion, a P/E ratio of -9.47 and a beta of 2.11.

Immunome (NASDAQ:IMNM – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, sell-side analysts anticipate that Immunome will post -2.26 earnings per share for the current year.

Insider Activity at Immunome

In related news, CFO Max Rosett sold 65,000 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer owned 54,037 shares in the company, valued at $1,184,491.04. The trade was a 54.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $20.47, for a total transaction of $753,296.00. Following the transaction, the director owned 369,347 shares in the company, valued at $7,560,533.09. The trade was a 9.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 139,438 shares of company stock worth $2,964,664 over the last quarter. 7.21% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Immunome by 285.6% during the 1st quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock valued at $17,094,000 after acquiring an additional 578,890 shares during the period. Edgestream Partners L.P. acquired a new position in shares of Immunome during the 1st quarter valued at $1,310,000. California State Teachers Retirement System lifted its position in shares of Immunome by 66.3% during the 1st quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock valued at $2,437,000 after acquiring an additional 44,432 shares during the period. Quantinno Capital Management LP acquired a new position in shares of Immunome during the 1st quarter valued at $222,000. Finally, Aristotle Atlantic Partners LLC acquired a new position in shares of Immunome during the 1st quarter valued at $2,734,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.